Galapagos News | finanzen.ch

Kurse + Charts + Realtime	News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (gross)	News + Adhoc	Bilanz/GuV	Termine	Strukturierte Produkte	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil		Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV
Historisch			Analysen

Kurse + Charts + Realtime

News + Analysen

Fundamental

Unternehmen

zugeh. Wertpapiere

Aktion

Kurs + Chart

Chart (gross)

News + Adhoc

Bilanz/GuV

Termine

Strukturierte Produkte

Portfolio

Times + Sales

Chartvergleich

Analysen

Schätzungen

Profil

Watchlist

Börsenplätze

Realtime Push

Kursziele

Dividende/GV

Historisch

Analysen

14.07.19	GILEAD AND GALAPAGOS ENTER INTO TRANSFORMATIVE RESEARCH AND DEVELOPMENT COLLABORATION (GlobeNewswire)
02.07.19	GILEAD ANNOUNCES INTENT TO SUBMIT NEW DRUG APPLICATION FOR FILGOTINIB TO U.S. FOOD AND DRUG ADMINISTRATION THIS YEAR (GlobeNewswire)
20.06.19	Galapagos increases share capital through warrant exercises (GlobeNewswire)
17.06.19	Transparency notification (GlobeNewswire)
11.06.19	Servier and Galapagos complete enrollment of global ROCCELLA Phase 2 clinical trial with GLPG1972/S201086 in knee osteoarthritis patients (GlobeNewswire)
29.05.19	GILEAD AND GALAPAGOS TO PRESENT LATEST DATA ON FILGOTINIB AT THE ANNUAL EUROPEAN CONGRESS OF RHEUMATOLOGY (EULAR 2019) (GlobeNewswire)
25.04.19	Galapagos reports on historic first quarter 2019 (GlobeNewswire)
23.04.19	Galapagos and MorphoSys announce initiation of GECKO Phase 2 study with MOR106 in atopic dermatitis patients (GlobeNewswire)
22.04.19	Ausblick: Galapagos stellt das Zahlenwerk zum vergangenen Quartal vor (finanzen.net)
10.04.19	Galapagos creates new warrant plans (GlobeNewswire)
29.03.19	Publication of the annual report and invitation to the annual shareholders' meeting (GlobeNewswire)
28.03.19	GILEAD AND GALAPAGOS REPORT UPDATED SAFETY INFORMATION FOR FILGOTINIB IN RHEUMATOID ARTHRITIS (RA) (GlobeNewswire)
28.03.19	GILEAD AND GALAPAGOS REPORT UPDATED SAFETY INFORMATION FOR FILGOTINIB IN RHEUMATOID ARTHRITIS (RA) (GlobeNewswire)
28.03.19	GILEAD AND GALAPAGOS ANNOUNCE FILGOTINIB MEETS PRIMARY ENDPOINT IN THE PHASE 3 FINCH 3 STUDY IN METHOTREXATE-NAÏVE RHEUMATOID ARTHRITIS PATIENTS (GlobeNewswire)
28.03.19	GILEAD AND GALAPAGOS ANNOUNCE FILGOTINIB MEETS PRIMARY AND KEY SECONDARY ENDPOINTS IN THE PHASE 3 FINCH 1 RHEUMATOID ARTHRITIS STUDY (GlobeNewswire)
20.03.19	Galapagos increases share capital through warrant exercises (GlobeNewswire)
21.02.19	Firmly on our way to becoming a fully integrated biopharma company (GlobeNewswire)
07.02.19	EVOTEC vergibt Lizenz für Fibrose-Programm an Galapagos - EVOTEC-Aktie leichter (Dow Jones) EVOTEC hat sich für die weitere Entwicklung eines potenziellen Wirkstoffs gegen fibrotische Erkrankungen der Leber und anderer Organe das belgische Biotech-Unternehmen Galapagos als Partner gesucht.» mehr
07.02.19	Evotec and Galapagos enter into collaboration in the field of fibrosis (GlobeNewswire)
08.01.19	Sands Capital reports 5.7% holding in Galapagos (GlobeNewswire)
07.01.19	Galapagos starts first Phase 1 trial with Toledo compound (GlobeNewswire)
06.01.19	Galapagos initiates NOVESA Phase 2a trial in patients with systemic sclerosis (GlobeNewswire)
04.01.19	Fibrocor and Galapagos sign partnership in fibrosis (GlobeNewswire)
21.12.18	Galapagos to Present at 37th Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
17.12.18	Galapagos reports initiation of ISABELA Phase 3 program with GLPG1690 in patients with Idiopathic Pulmonary Fibrosis (IPF) (GlobeNewswire)
27.11.18	Galapagos receives Fast Track designation from FDA for GLPG1972/S201086 in osteoarthritis (GlobeNewswire)
26.11.18	Transparency notification (GlobeNewswire)
23.11.18	Galapagos increases share capital through warrant exercises (GlobeNewswire)
31.10.18	Galapagos reports initiation of PINTA Phase 2 trial with GLPG1205 in patients with Idiopathic Pulmonary Fibrosis (IPF) (GlobeNewswire)
24.10.18	Hallmark third quarter 2018 and Annual R&D Update at Galapagos (GlobeNewswire)
24.10.18	Galapagos and AbbVie restructure CF collaboration (GlobeNewswire)
24.10.18	Topline interim results of FALCON trial Part 1 in CF (GlobeNewswire)
23.10.18	Ausblick: Galapagos stellt Quartalsergebnis zum abgelaufenen Jahresviertel vor (finanzen.net)
22.10.18	POSITIVE TRIAL RESULTS WITH FILGOTINIB IN PSORIATIC ARTHRITIS AND ANKYLOSING SPONDYLITIS BOTH PUBLISHED IN THE LANCET (GlobeNewswire)
21.10.18	PHASE 3 DATA ON FILGOTINIB IN BIOLOGIC-EXPERIENCED RHEUMATOID ARTHRITIS TO BE PRESENTED AT 2018 ACR/ARHP ANNUAL MEETING (GlobeNewswire)
03.10.18	Galapagos increases share capital through warrant exercises (GlobeNewswire)
24.09.18	Galapagos reports initiation of global ROCCELLA Phase 2 clinical trial with GLPG1972/S201086 in osteoarthritis patients (GlobeNewswire)
17.09.18	Galapagos issues new shares as result of public offering (GlobeNewswire)
17.09.18	Galapagos announces closing of public offering of American Depositary Shares for gross proceeds of €296.2 million (GlobeNewswire)
13.09.18	Galapagos and MorphoSys announce start of a Phase 1 subcutaneous bridging study with MOR106 (GlobeNewswire)

Aktien Top/Flop

SMI
SPI
SLI
SMIM
DAX
ESTOXX
Dow Jones
S&P 500
NASDAQ 100
Nikkei 225

Part Grp Hldg	1’277.50	0.83 %	K V
Lonza Grp	543.60	0.41 %	K V
Kuehne+Nagel Int	203.10	0.25 %	K V
Holcim	89.04	0.20 %	K V
Alcon	76.40	0.10 %	K V
UBS Group	27.87	-1.06 %	K V
Sika	222.90	-1.46 %	K V
Swiss Re	129.60	-1.78 %	K V
Givaudan	3’978.00	-2.04 %	K V
Nestle	73.62	-2.13 %	K V

mehr

Portfolioname Watchlistname
Portfolio
Name
Typ
Valor / ISIN
Börse
Anzahl
Aktueller Kurs
Kurszeit
Kaufpreis
Kaufdatum
Kaufwert	CHF
	Hinzufügen Speichern

Nachrichten zu Galapagos

Aktien Top/Flop

Galapagos Peer Group Nachrichten

Meistgelesene Nachrichten